BioNTech and Pfizer received U.S. FDA approval for their 2026-2027 COVID-19 Vaccine formula targeting the XFG variant, with shipping beginning immediately. The authorization covers adults ages 65 years and older and higher-risk individuals ages 5 through 64, supporting near-term availability in U.S. pharmacies, hospitals and clinics.
Key Highlights
- Doses are expected to reach U.S. pharmacies, hospitals and clinics in the coming days.
- More than five billion COMIRNATY doses have been distributed globally to date.
- Shipping of the 2026-2027 vaccine begins immediately.
Availability is expected in U.S. pharmacies, hospitals and clinics in the coming days.
XFG Vaccine Clears FDA Review
The authorization rests on clinical, non-clinical and real-world evidence previously submitted by BioNTech (NASDAQ: BNTX) and Pfizer. Manufacturing and quality information, together with non-clinical data, showed that the XFG-adapted vaccine generated strong immune responses against XFG and other contemporary SARS-CoV-2 lineages.
The approval applies to the specified age groups and higher-risk population.
Immediate U.S. Distribution
Shipping of the 2026-2027 vaccine begins immediately. The companies said doses will become available across the United States through pharmacies, hospitals and clinics in the coming days.
The formula was selected for the fall 2026 U.S. vaccination season. BioNTech and Pfizer said the updated vaccine targets XFG in line with the FDA’s guidance on matching contemporary circulating variants.
Global Dose Distribution
BioNTech’s forward-looking statements include expectations regarding manufacturing, distribution and supply, along with anticipated changes in COVID-19 vaccine demand. The companies also identified future Demand for initial or booster doses as an area of uncertainty.
Peers Moving on This News
Source(s)
- https://www.sec.gov/Archives/edgar/data/1776985/000177698526000059/form6-kxfgvariantvaccinefd.htm
FAQs
Q: What evidence supported the FDA authorization?
A: The authorization relied on clinical, non-clinical and real-world evidence submitted by BioNTech and Pfizer. Manufacturing, quality and non-clinical data showed strong immune responses against XFG and other contemporary SARS-CoV-2 lineages.
Q: What supports the FDA authorization of the XFG-adapted vaccine?
A: The authorization is based on clinical, non-clinical and real-world evidence previously submitted by BioNTech and Pfizer. Manufacturing and quality information also supported strong immune responses against XFG and other contemporary SARS-CoV-2 lineages.
Q: When and where will the 2026-2027 vaccine become available?
A: Shipping begins immediately, with doses expected to become available across the United States through pharmacies, hospitals and clinics in the coming days. The vaccine was selected for the fall 2026 U.S. vaccination season.
Q: What uncertainties could affect future vaccine demand and distribution?
A: The companies identified future demand for initial or booster doses as an area of uncertainty. BioNTech’s forward-looking statements also cover manufacturing, distribution, supply and anticipated changes in COVID-19 vaccine demand.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.